Orkla ASA
OSE:ORK

Watchlist Manager
Orkla ASA Logo
Orkla ASA
OSE:ORK
Watchlist
Price: 101.6 NOK 2.16% Market Closed
Market Cap: 101.4B NOK
Have any thoughts about
Orkla ASA?
Write Note

Earnings Call Analysis

Q2-2024 Analysis
Orkla ASA

Strong Growth Amid Market Adjustments

Orkla achieved a 13% growth in adjusted EBITDA for Q2, driven by a 22% improvement in underlying EBIT for its consolidated companies. EBIT adjusted margin rose to 12.3%, up from 10.5% YoY. Orkla Foods Europe saw 19% underlying EBITDA growth despite some volume decline. Confectionery & Snacks reported an 11% organic sales growth. Jotun's sales growth was broad-based, though affected by currency fluctuations. Lower raw material costs also contributed positively. For 2024, Orkla aims for low-mid single-digit improvements in input costs.

Strong Financial Performance and Market Share Gains

In the second quarter, Orkla demonstrated solid financial performance with a 7% increase in adjusted earnings per share, reaching NOK 1.66. The company reported a 13% growth in adjusted EBITDA, which was driven by a significant 22% improvement in underlying adjusted EBIT across the consolidated portfolio companies. Market share remained stable, and volume growth was positive overall, signaling the company's robust market position.

Division Highlights: Orkla Foods Europe and Confectionery & Snacks

Orkla Foods Europe achieved an impressive 19% growth in underlying EBITDA adjusted, mainly due to successful restructuring programs and effective category management, despite facing soft volume trends. Orkla Confectionery & Snacks also witnessed a notable improvement, with market share recovery in the biscuit category thanks to better service levels and factory performance.

Performance in Ingredients and External Factors

Orkla Food Ingredients showed mixed results with strong performance in bakery and plant-based clusters but challenges in sweet ingredients. New initiatives are being implemented to address these issues. On the other hand, Jotun experienced broad-based sales growth, though currency translation effects negatively impacted EBITDA.

Strategic Steps and Long-term Goals

Orkla remains committed to driving organic value within its existing portfolio, taking significant steps towards its financial targets set for 2026. Key actions include closing the Orkla Food Ingredients partnership in April and announcing the sale of Lilleborg to Solenis in June. The evaluation of the Hydro Power assets is ongoing, with a detailed update expected in 2025 regarding the IPO readiness of Orkla India.

Revenue and Profitability Trends

Group operating revenues increased by 1% with 3.3% organic sales growth for consolidated portfolio companies. Adjusted EBIT margins for these companies improved to 9.7% from 9.3% in the previous quarter, aided by easing raw material costs.

Cash Flow and Debt Management

Cash flow from operations totaled NOK 3.2 billion year-to-date, driven by EBIT growth, reduced investments, and lower inventory levels. Net interest-bearing debt was NOK 20 billion at the end of June, influenced by dividends paid out and proceeds from strategic sales.

Guidance and Future Outlook

The management expects raw material costs to improve in the low mid-single-digits throughout 2024. For Orkla Foods Europe, the volume mix growth year-to-date was at -1.9%, accounting for the Easter effect. Improvement in the biscuit factory continues to be on track, with significant recovery anticipated from the previous year's losses.

Earnings Call Transcript

Earnings Call Transcript
2024-Q2

from 0
K
Kari Lindtvedt
executive

Good morning, and welcome to the presentation of Orkla's Second Quarter Results. My name is Kari Lindtvedt, I'm Head of Investor Relations. Our speakers today will be President and CEO, Nils Selte; and our newly appointed CFO, Arve Regland.

Nils will start by summarizing Q2 and also share some highlights from the first half of 2024, and then Arve will summarize and give you more details on the quarter we are reporting. Before Q&A, Nils will summarize our main messages from today. Throughout the presentations today, you're welcome to post questions in the live chat, and we will answer your questions at the end of the presentations.

But now let's begin. I'll leave the floor to Nils.

N
Nils Selte
executive

Thank you, Kari, and good morning to everyone. I'm happy to see that the financial results for Q2 continued to show progress on several key drivers, in line with our communication in Q1 this year. Adjusted earnings per share in Q2 were NOK 1.66, 7% from the same quarter last year. We report EBITDA adjusted growth of 13% for the group, driven by underlying EBIT adjusted improvement of 22% in the consolidated portfolio companies.

I'm also happy to see volumes remaining on in positive territory and overall market share development, showing signs on the positive side. In addition, the EBIT adjusted margin showed good progress in the quarter. The development in raw materials price is best described as polarized, but we are starting to see slight positive effects in our Q2 figures.

This slide provides more details on the financial performance of our reportable companies in the quarter. As you can see from the boxes at the top, growth in Q2 continued to be broad-based on both EBIT adjust and margin development. Underlying EBIT adjusted for most of the consolidated portfolio companies saw growth. As the largest portfolio company, I would like to highlight Orkla Foods Europe. Their restructuring programs and effective category management secured 19% underlying EBITDA adjusted growth in the quarter despite volumes on the soft side.

For Orkla Confectionery & Snacks, I'm also happy to see that the situation in the biscuit factory continues to improve. Service levels are good, and market shares are returning in their category. Orkla Food Ingredients reported strong development in both the bakery and plant-based clusters. The development in sweet ingredients was more challenging this quarter, and the Orkla Food Ingredients management has already identified several initiatives.

Jotun also reported broad-based sales growth in Q2. However, negative currency translation effects led to a slight negative EBITDA development in the quarter. For the rest of the year, Jotun expects sales growth but at a lower rate than in the past years due to strong comparables.

Before I hand over to Arve, I would like to share some highlights from the first half of 2024. We have been very clear that our number one priority is to drive organic value in the existing portfolio. As you see on the next slide, we are progressing well towards the financial targets that were announced in November last year. We are also committed to reduce complexity in the portfolio. This will take time, and we will not let ourselves be rushed into any decisions. Long-term value creation stays firm in our decision-making.

That said, we have already taken some important first steps during 2024. The Orkla Food Ingredients partnership was closed in April. And in June, we announced the sales of Lilleborg to Solenis. At our Capital Markets Day in November, I mentioned that we will explore options for how to best create value from our Hydro Power assets. The evaluation is still ongoing, and we will give more -- give you more information on the outcome of our assessment once we have concluded.

Also at the Capital Markets Day, I said that we were going to initiate a process to consider structural opportunities for Orkla India, including conducting an IPO readiness study. The result of the study are encouraging, and we will now proceed with an evaluation of accessing the capital markets in India. Any conclusion should not be expected until sometimes 2025. As mentioned, we are progressing well towards delivering on our financial ambitions per Q2 '24.

This slide show the targets set by the consolidated portfolio companies for the period ending 2026 and the status on progress as per first half 2024. It is still early days, and we expect to see fluctuations going forward. But still, I must add that I'm quite impressed by all the hard work being carried out in the portfolio companies.

And I'm very glad to see that the initiatives set out in the full potential plans are starting to deliver positive effects. With that, I will leave the floor to Arve for more details on the financials.

A
Arve Regland
executive

Thank you, Nils, and good morning, everyone. I will take you through the financial performance of the group and the portfolio companies for the second quarter. Group operating revenues grew by 1% in the second quarter, with organic sales growth for the consolidated portfolio companies of 3.3%. EBIT adjusted for the consolidated portfolio companies was up 17%, driven by strong underlying growth and improved margins for most of our portfolio companies.

Lower EBIT adjusted for financial investments was mainly driven by lower power prices for Hydro Power as well as fewer handover of apartments in Orkla Real Estate. Other income and expenses was mainly impacted by profit from the sale of Lilleborg and costs related to the sale of 40% of Orkla Food Ingredients. Profit from Jotun and other associates was NOK 529 million in the quarter, with Jotun continuing to deliver strong results.

Net interest and other financial items amounted to NOK 275 million. The average interest rate was 5.7% compared to 4.9% in the same quarter last year, driven by higher interest rate levels and the inclusion of external debt in Orkla Food Ingredients. Tax costs totaled NOK 492 million equivalent to a tax rate of 23.3%.

Reduction in tax rate compared to last year is mainly due to lower resource rent taxes for Hydro Power and repeal of the windfall tax. Profit in noncontrolling interest was NOK 106 million in the quarter, the increase being due to Orkla Food Ingredients transaction. And more details on the financial impact of this transaction can be found in the appendix.

Overall, profit after tax to Orkla shareholders ended at NOK 2 billion, corresponding to an adjusted earnings per share of NOK 1.66, an increase of 7% compared to the same quarter last year. Rolling 12-month EBIT adjusted margin for the consolidated portfolio companies was 9.7% in the quarter, up from 9.3% in Q1. As Nils mentioned, margins have been positively affected by easing pressure on raw materials. And in Q2, we saw a reduction compared to last year. The right-hand table illustrates broad-based improvement with both Orkla Foods Europe and Orkla Confectionery & Snacks delivering solid margin increases.

Organic growth in the quarter was 3.3%, split into 2.3% volume mix and 1% price. We see price growth coming down in line with lower inflation and reduction in raw material costs. Volume mix in Q2 was positively affected by the timing of Easter. Year-to-date, volume mix growth was 1.7%. It's good to see two consecutive quarters of positive volume mix performance and as shown in the table to the right, the positive volume mix growth was broad-based.

Total cash flow from operations year-to-date amounted to NOK 3.2 billion compared to NOK 2.1 billion in the same quarter last year. The increase was driven by EBIT growth in the consolidated portfolio companies, lower net replacement investments and reduced inventory levels. Several portfolio companies have a reduction in net replacement investments. A large part of the reduction was linked to Orkla Confectionery & Snacks investment in a new biscuit factory last year. Reduction in operating cash flow from financial investments was related to the decline in profits from Hydro Power and real estate, as previously mentioned.

A breakdown of cash conversion per consolidated portfolio company can be seen in the table to the right. Net interest-bearing debt, including leases, amounted to NOK 20 billion at the end of June, up from NOK 18.8 billion at the end of last year. The increase is mainly related to a dividend of NOK 6 billion paid to shareholders in May, offset by cash flow from operations and net proceeds from the sale of 40% of Orkla Food Ingredients and the sale of Lilleborg.

Further, Orkla has received NOK 474 million in dividends from Jotun, corresponding to 50% of the total dividend from Jotun for the financial year 2023. The remaining amount will be received in the second half of '24. At the end of the quarter, net interest-bearing debt amounted to 2x EBITDA last 12 months. If excluding net interest-bearing debt and EBITDA of Orkla Food Ingredients, which now have a stand-alone financing with no recourse to Orkla, net interest-bearing debt to EBITDA would be 1.6x.

Now let's take a closer look at the performance of the portfolio companies, starting with Jotun. Yet again, Jotun delivered a solid quarter with reported sales growth of 4%. Adjusted for negative currency translation effects, sales growth was 7%. Year-to-date sales growth has been particularly strong in Marine, Protective and Powder, which all have delivered underlying double-digit sales growth.

Sales grew in all regions with the exception of Southeast Asia and Pacific, where sales remained flat. Jotun's EBITA margin remains strong in the second quarter. The company achieved a margin of 22% year-to-date despite a significant negative impact from devaluation of the Egyptian pound in the first quarter. Reported EBITA growth came in at minus 2% in Q2. However, excluding currency translation effects, underlying earnings are up 2% in the quarter and 9% year-to-date.

Moving on to Orkla Foods Europe. Underlying EBIT adjusted growth was 19% in the quarter, positively impacted by savings from cost initiatives in Norway, Sweden and The Czech Republic. Orkla Foods Europe experienced improved contribution ratio from stronger focus on category and product profitability. The organic sales growth was 0.7% in the quarter, driven by price growth. Timing of Easter had a positive effect on the figures. Negative volume mix development was driven by reduced purchasing power, selected customer actions as well as complexity reductions in line with what was communicated at the Capital Markets Day.

In terms of market shares, the trend was positive in Denmark on back of strong campaigns. In Norway, development was fairly stable and on an overall level, slightly negative in our other markets. Despite higher A&P investment, the EBIT adjusted margin ended at 12.3%, up from 10.5% last year.

Next portfolio company is Orkla Confectionery & Snacks. Organic sales growth was 11% in the quarter, split into 4.3% price and 6.7% volume mix. We saw a positive shift in market share for all main categories in the quarter in an overall growing market. The EBIT adjusted in the quarter ended at NOK 255 million with an underlying EBIT adjusted growth of 29%. EBIT adjusted margins grew to 11.1% compared to 9.5% last year, supported by a 1.2 percentage point increase in contribution margin improvements in a new biscuit factory and operational leverage from volume increase.

Service level and productivity from the new biscuit factory continued to improve during the quarter. Approximately half of the underlying EBIT adjusted growth in the quarter was driven by improvement in the biscuit factory. A&P investment increased in the quarter, while raw material costs with the exception of cocoa began to stabilize in most categories. Regarding cocoa, higher prices create uncertainty about volumes going forward.

Let's proceed to Orkla Food Ingredients. Underlying EBIT adjusted growth was 3.4% in the quarter. Price growth was minus 2.3% and must be seen in relation to lower raw material costs in several key categories. Contribution ratio increased from 28.2% to 30% due to price management. The 3 different clusters delivered a mixed picture with both bakery and plant based delivering solid volume mix and profitability improvement, while performance in sweet was weak. Due to the low results in the first half year, a program of mitigating actions has recently been launched in the sweet cluster.

Next in line is Orkla Health. Organic revenue growth was 7.3% in the quarter, split by 2.9% price and 4.4% volume mix. Volume/mix growth was driven by the direct-to-consumer businesses and the global brands, Möller's’ and Jordan. Underlying EBIT adjusted growth was 12.4% with a corresponding EBIT adjusted margin of 14.7%.

Margins were somewhat muted due to the broad-based cost inflation, increased A&P investments and higher maintenance costs from increased production volumes as well as continued margin pressure in the food supplements category in the Nordics. In line with the strategy of accelerating international expansion for global brands and new market entries for NutraQ, investments in advertising and SG&A continued to increase to support future growth.

The next portfolio company is Orkla India. Organic growth was 9.4% in the quarter, positively affected by financial incentives provided by the Government of India of NOK 20 million. Last year, these incentives were mainly received in the fourth quarter. Adjusting for this, volume mix growth in the quarter was 6.7%, driven by the international business unit. Sales in the domestic business units were soft due to muted private consumption growth. Adjusted for government grants, underlying EBIT adjusted growth was 21.9% in the quarter with a corresponding margin of 14.9%. The growth was driven by higher contribution margin, mainly due to declining cost of key raw materials.

Moving on to The European Pizza Company. Consumer sales for New York Pizza recovered in the Netherlands after a soft start to the year in key markets. Da Grasso in Poland also continued its good momentum while Kotipizza was negatively affected by a weaker consumer sentiment in Finland. Organic growth and underlying EBIT adjust were notably affected by the ongoing restructuring in Germany, which is now operating at a smaller but more profitable base. EBIT adjusted margins were 11.7% in the quarter, up from 7.2% in the same period last year.

Let's proceed to Orkla Home & Personal Care. Organic growth was 10.9% in the quarter, supported by robust volume mix performance in the Norwegian market and in contract manufacturing, positively impacted by new innovations. Market share development was strong in the Norwegian and Swedish grocery sector, both in personal care and home care. Underlying EBIT adjusted grew by 22% on back of somewhat muted comparables last year. EBIT adjusted margins increased to 12.1% versus 10.7% in the same quarter last year. The improvement is linked to lower SG&A costs, but countered by A&P investments to support new product launches and hero brands.

As regards to remaining portfolio companies, more details can be found in the quarterly report. Still, I would like to highlight the positive development in Orkla Health Care. In addition, I would like to mention that the financial results for Lilleborg only include the first 2 months in this quarter in connection with sale effective from the 1st of June. From next quarter, Lilleborg will no longer be included in the financial reporting.

Then I would like to hand the floor back to Nils.

N
Nils Selte
executive

Thank you, Arve. Our portfolio companies have delivered a good first half 2024, in line with our ambition to drive organic value. The portfolio companies achieved high EBIT adjusted growth, margin expansion and increased return on capital employed. We continue to increase our investments in advertising and promotion and our improving operating margin at the same time. In most of our portfolio companies, we are also continuing the positive trend of improving cash conversion.

Wrapping up, I'm glad to see that we are on our way to delivering on the strategic ambitions communicated at our Capital Markets Day. And I believe that the potential of our new operating model is becoming more visible. Then as a final comment, I want to say a big thank to you, Kari, for your valuable contribution to Orkla since you started more than 17 years ago, and especially as our SVP, Investor Relations, last 4 years. I admire your skills and expertise, and I wish you all the best in your new job.

With that, I leave the floor to the Q&A.

K
Kari Lindtvedt
executive

Thank you for those kind words, Nils. The pleasure has been the same. Let's now take some questions. We have a couple from the web, but let me start by asking if there are any questions from the audience. Please state your name and company.

Let's move to some questions from the web then, starting with two questions from Petter Nyström, ABG. First question, you mentioned a slightly positive effect from raw material costs in Q2. If we assume raw material costs and FX to stay at current levels, do you expect this effect to be larger in the second half of the year?

N
Nils Selte
executive

We have said to the market in the last quarters that we expect low mid-single-digit improvements in the input costs this year. And I think that goes for the whole year 2024 and we just want to deplete that message market.

K
Kari Lindtvedt
executive

And the second question from Petter. Solid overall volume development in Q2, but for Foods are struggling with a 1.6% decline. You mentioned select customer actions and complexity reduction. Can you share some more insight on this?

N
Nils Selte
executive

Orkla Foods Europe, we see some trading down effects in some of the markets, especially Sweden, Finland and the Czech. We also see some -- we said customer action, and that is kind of due to negotiations with the customers. That has also been the case. But we see also in the same period, good effects or better development in the Norwegian and the Danish market.

K
Kari Lindtvedt
executive

Then we have 3 questions from Ole Martin Westgaard. I'll take them one at the time. Question one, how was your market share development in Q2? And how do you see the competition from private label?

N
Nils Selte
executive

We see -- let's start with the last one. I think we see diminishing private label effects through this year. So that's on the positive side. We have said also that we see a positive market development in some of our portfolio companies, and we see flat on some of the others and slightly negative in a few of them. I think Arve commented on it in his presentation, and we also described this quite details in the report that we have issued. So I think that covers that question.

K
Kari Lindtvedt
executive

And then the second question from Ole Martin. What have you learned from the IPO readiness study in India?

N
Nils Selte
executive

As I said, we've got positive feedback from that study. And as I also said, that we will now assess if we are going further with to access the capital markets in India. And as I also said, we will revert to the market in 2025 with more information when we have kind of come down the road with that work. It's a lot of things to do before we're good to go.

K
Kari Lindtvedt
executive

Absolutely. And then the third and final question from Ole Martin. Can you update us on the biscuit factory? What do you expect in the coming quarter? Are problems solved?

N
Nils Selte
executive

We can repeat what we said at the Capital Markets Day, that a significant part of the loss from 2023 will be regained during this year. And I think the message is still the same. So we are on track on what we said.

K
Kari Lindtvedt
executive

Then Eirik Rafdal, two questions. First one, cocoa prices. Based on your hedging profile and the prices you are hedging at today, all else equal, how much will cost come up in Confectionery & Snacks and on group level? And when should we start to see effects in the P&L?

N
Nils Selte
executive

We have said that we are pretty much covered for this year. We haven't said that which price level we have covered volume and price for this year. So we also said that if the market stays at this level, we will start to see effects into the 2025 figures, but we will also have some slight effect also in the end of this year, but we haven't been precise, and we will not be precise on guiding on that.

K
Kari Lindtvedt
executive

And second question from Eirik. You note market share gains across multiple portfolio companies and multiple geographies. Do you have an idea of who is losing shares? Is it private label or competing branded goods?

N
Nils Selte
executive

We have said that mostly private label has taken market share from us over the last few years, and we still see the same pattern. We see still some trading down effects in some selected markets. We see that in Foods Europe and Sweden, we see it in Finland, and we also see it in the Czech.

K
Kari Lindtvedt
executive

Then a question from Patrik Shludby. What are you going to do with the money made from selling Lilleborg?

N
Nils Selte
executive

That's up to the Board to decide. But I think it's not a big amount compared to the whole system of Orkla. So I think that will be something that the Board will consider when we file for the 2024 annual report.

K
Kari Lindtvedt
executive

And then, HĂĄkon Fuglu, SE Banken. Adjusted for Easter effects, what would volume growth have been for Orkla Foods Europe in the quarter?

A
Arve Regland
executive

I think if you look at -- it's better now to look at year-to-date numbers because that's more precise on the -- then you're diminishing the Easter effect. So if you look at the year-to-date numbers, I think you got answer.

K
Kari Lindtvedt
executive

And those are minus 1.9% year-to-date.

A
Arve Regland
executive

Yes.

K
Kari Lindtvedt
executive

That covers all the questions from the web. Are there any questions in the audience? None? Okay. Before rounding off, I'd like to remind you that we report our third quarter results on the 29th of October. Thank you for joining, and have a nice rest of the day.